IOWA Diabetes Data & Forecasts

Institute for Alternative Futures

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	3,026,400	3,020,500	2,993,200	2,955,200
Prediabetes	807,700	832,700	849,900	840,200
Diagnosed diabetes	210,000	248,300	276,600	294,900
Undiagnosed diabetes	82,700	92,800	98,100	99,100
Total with diabetes (diagnosed and undiagnosed)	292,700	341,100	374,700	394,000
Complications:				
Visual impairment	34,400	39,500	42,700	44,200
Renal failure	500	570	610	630
Leg amputations	430	470	480	470
Annual deaths attributable to diabetes	2,260	2,550	2,700	2,730
Total annual cost (2015 dollars)	$3.0 B	$3.4 B	$3.7 B	$3.9 B
Annual medical costs	$2.3 B	$2.6 B	$2.8 B	$2.9 B
Annual nonmedical costs	$0.7 B	$0.8 B	$0.9 B	$1.0 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	494,600	556,500	619,200	663,200
Prediabetes	252,200	283,800	315,800	338,200
Diagnosed diabetes	93,500	105,200	117,000	125,300
Undiagnosed diabetes	34,600	39,000	43,300	46,400
Total with diabetes (diagnosed and undiagnosed)	128,100	144,100	160,400	171,800
Complications:				
Visual impairment	17,500	19,200	20,800	21,700
Renal failure	290	310	340	350
Leg amputations	220	230	230	230
Annual deaths attributable to diabetes	1,560	1,710	1,760	1,720
Total annual cost (2015 dollars)	$1.6 B	$1.8 B	$2.0 B	$2.2 B
Annual medical costs	$1.5 B	$1.7 B	$1.9 B	$2.1 B
Annual nonmedical costs	$0.1 B	$0.1 B	$0.1 B	$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.